Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strat
The Investor Relations website contains information about Blueprint Medicines Corp.'s business for stockholders, potential investors, and financial analysts.
ir.blueprintmedicines.com
BLU-945 Plus Osimertinib Has Favorable Tolerability, Warrants Further Development in EGFR+ NSCLC
BLU-945 alone or in combination with osimertinib demonstrated early signals of clinical activity and was well tolerated in heavily pretreated patients with EGFR-mutant non–small cell lung cancer.
www.onclive.com
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS9156
http://www.biospectator.com/view/news_view.php?varAtcId=11373
'4세대 EGFR TKI' 나올까..블루프린트, 'BLU-945' ”내년 임상"
3세대 EGFR TKI 약물 '타그리소(Tagrisso, Osimertinib)'의 한계를 극복할 가능성을 보여주는 ‘4세대 EGFR TKI’의 비임상 결과가 발표됐다.블루프린트
www.biospectator.com
https://www.thebell.co.kr/free/content/ArticleView.asp?key=202111101644067800108427 2022.11.4
美 블루프린트 vs 브릿지바이오, 4세대 EGFR TKI 경쟁
국내 최고 자본시장 미디어 thebell이 정보서비스의 새 지평을 엽니다.
www.thebell.co.kr
'신약개발 소식, 해외 논문들' 카테고리의 다른 글
| MARIPOSA, MARIPOSA-2 임상시험 (0) | 2024.02.01 |
|---|---|
| BBT-207, 브릿지바이오 (1) | 2024.01.02 |
| "수술없이 암세포 99% 파괴"…획기적 기술 찾았다 (1) | 2024.01.01 |
| 서울대중입자치료기 홈피 (0) | 2023.10.23 |
| 킴리아주(Cart-T, 백혈병 치료) 효과 (0) | 2023.10.09 |